Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study

Knuijver, Thomas, Schellekens, Arnt, Belgers, Maarten, Donders, Rogier, van Oosteren, Toon, Kramers, Kees, Verkes, Robbert · 2021 · Addiction

AI-extracted · unverified · confirm at source

Dutch hospital study (n=14). QTc prolongation median ΔQTcMax 102ms (SD 36ms, range 40–168ms); 50% reached >500ms. Prolongation >450ms lasted >24h in 6 patients. No torsade. Severe but reversible ataxia in all. 11/14 did not return to morphine.

Dosing: 10mg/kg (oral)

Sample size: 14

Safety data present: QTC, ELECTROLYTE

Contraindications: cardiac disease history, ventricular fibrillation history, long QT syndrome, syncope history, QTc >450ms men / >470ms women, serum potassium >5.0 or <3.5 mmol/L, severe liver dysfunction, severe renal dysfunction (MDRD <30), pregnancy, QT-prolonging medications, CYP2D6 inhibitors, psychosis history, severe depression, suicidality